Nintedanib Adalvo (Nintedanib)

Nintedanib blocks several receptor tyrosine kinases—VEGFR, FGFR and PDGFR—thereby inhibiting the signals that drive fibroblast growth, migration and transformation. This interruption reduces the deposition of scar tissue in the lungs and mitigates the fibrotic process that characterises progressive interstitial lung diseases.

The specific dose and dosing schedule are determined by the prescribing physician based on the patient’s clinical condition, weight, renal and hepatic function, and other individual factors. Healthcare providers follow the approved prescribing information to set an appropriate regimen.

Safety data for nintedanib in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It is generally advised to avoid use during pregnancy and to discuss alternative options with a healthcare professional. Breastfeeding considerations should also be evaluated with a physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The primary alternative antifibrotic is pirfenidone, which also slows lung function decline in idiopathic pulmonary fibrosis. Nintedanib targets a broader range of tyrosine kinases, potentially offering benefit in systemic sclerosis‑associated disease, whereas pirfenidone’s mechanism focuses on oxidative stress and cytokine modulation. Choice depends on patient tolerance, comorbidities and physician assessment.

Nintedanib Adalvo should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments.

The medication is taken orally, usually with food to lessen gastrointestinal discomfort. Patients should swallow the tablet whole with a full glass of water and follow the dosing instructions provided by their prescriber. Consistency in timing each day helps maintain stable drug levels.

Serious risks include potential liver injury, significant bleeding events, cardiovascular complications such as myocardial infarction, severe infections, gastrointestinal perforation, and rare but severe skin reactions like Stevens‑Johnson syndrome. Patients should be monitored regularly for signs of these events and report any concerning symptoms promptly.

Nintedanib is contraindicated in patients with severe hepatic impairment, active bleeding disorders, or uncontrolled cardiovascular disease. It should also be avoided in pregnant individuals and those who are breastfeeding unless the benefits outweigh the risks. A thorough medical history and baseline laboratory tests are essential before initiating therapy.